HK1209024A1 - Nucleophilic catalysts for oxime linkage - Google Patents

Nucleophilic catalysts for oxime linkage

Info

Publication number
HK1209024A1
HK1209024A1 HK15109408.0A HK15109408A HK1209024A1 HK 1209024 A1 HK1209024 A1 HK 1209024A1 HK 15109408 A HK15109408 A HK 15109408A HK 1209024 A1 HK1209024 A1 HK 1209024A1
Authority
HK
Hong Kong
Prior art keywords
oxime linkage
nucleophilic catalysts
nucleophilic
catalysts
oxime
Prior art date
Application number
HK15109408.0A
Other languages
English (en)
Chinese (zh)
Inventor
Juergen Siekmann
Stefan Haider
Hanspeter Rottensteiner
Peter Turecek
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/488,043 external-priority patent/US8809501B2/en
Application filed by Baxter Int filed Critical Baxter Int
Publication of HK1209024A1 publication Critical patent/HK1209024A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15109408.0A 2012-05-16 2015-09-24 Nucleophilic catalysts for oxime linkage HK1209024A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647814P 2012-05-16 2012-05-16
US13/488,043 US8809501B2 (en) 2009-07-27 2012-06-04 Nucleophilic catalysts for oxime linkage
PCT/US2013/041280 WO2013173543A1 (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage

Publications (1)

Publication Number Publication Date
HK1209024A1 true HK1209024A1 (en) 2016-03-24

Family

ID=48579473

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109408.0A HK1209024A1 (en) 2012-05-16 2015-09-24 Nucleophilic catalysts for oxime linkage

Country Status (13)

Country Link
EP (3) EP4019049A1 (ja)
JP (5) JP6195611B2 (ja)
KR (4) KR102287040B1 (ja)
CN (2) CN109620963B (ja)
AU (1) AU2013204754C1 (ja)
BR (1) BR112014028636B1 (ja)
CA (1) CA2873756C (ja)
EA (2) EA035506B1 (ja)
HK (1) HK1209024A1 (ja)
MX (1) MX360594B (ja)
NZ (4) NZ701945A (ja)
SG (3) SG11201407597XA (ja)
WO (2) WO2013173557A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
CN117860868A (zh) * 2016-11-14 2024-04-12 诺华股份有限公司 用于治疗软骨损伤和关节炎的方法和组合物
JP7002036B2 (ja) * 2016-11-17 2022-01-20 パナソニックＩｐマネジメント株式会社 膜電極接合体および固体酸化物形燃料電池
WO2018112669A1 (en) * 2016-12-23 2018-06-28 Realist Pharma, Inc. Ganglioside carbohydrate structures and uses thereof
CN108503901B (zh) * 2018-04-17 2020-07-07 哈尔滨工业大学 一种抗菌普鲁兰多糖/壳聚糖复合食品包装膜的制备方法
AU2020210630A1 (en) 2019-01-23 2021-08-05 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
US11865134B2 (en) 2021-02-26 2024-01-09 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2001087922A2 (en) 2000-05-16 2001-11-22 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7026440B2 (en) 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
WO2004024761A1 (en) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Hasylated polypeptides, especially hasylated erythropoietin
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
JP4674702B2 (ja) 2003-04-09 2011-04-20 バイオジェネリクス エージー グリコペギレ−ション法およびその方法により生成されたタンパク質／ペプチド
EP1653991A2 (en) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugates of a polymer and a protein linked by an oxime linking group
RU2333223C2 (ru) 2003-08-12 2008-09-10 Лайпоксен Текнолоджиз Лимитед Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005055946A2 (en) 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
EP3184551A1 (en) 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialic acid derivatives
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
JP5022231B2 (ja) 2004-12-27 2012-09-12 バクスター・インターナショナル・インコーポレイテッド ポリマー−フォンビルブラント因子結合体
EP1896082B1 (en) 2005-06-16 2012-12-26 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2059527B1 (en) 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Modified glycoproteins
US8637007B2 (en) 2006-12-15 2014-01-28 Baxter International Inc. Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
EP3081233B1 (en) * 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
KR102068133B1 (ko) * 2009-07-27 2020-01-20 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
LT2598172T (lt) * 2010-07-30 2019-08-26 Baxalta GmbH Nukleofiliniai katalizatoriai, skirti oksiminei jungčiai sudaryti
KR101560541B1 (ko) * 2012-04-13 2015-10-19 아우토리브 디벨롭먼트 아베 에어백 모듈과 스티어링 휠의 조립체
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage

Also Published As

Publication number Publication date
KR102287040B1 (ko) 2021-08-09
JP2019089810A (ja) 2019-06-13
EP2849795B1 (en) 2022-04-06
JP7014844B2 (ja) 2022-02-01
EA028186B9 (ru) 2018-05-31
EA035506B1 (ru) 2020-06-25
JP7304402B2 (ja) 2023-07-06
NZ738846A (en) 2019-05-31
JP2017145260A (ja) 2017-08-24
EA201492115A1 (ru) 2015-05-29
SG11201407597XA (en) 2014-12-30
KR20210041629A (ko) 2021-04-15
EP4019049A1 (en) 2022-06-29
KR102110622B1 (ko) 2020-05-14
EP2849795A1 (en) 2015-03-25
CN104487095B (zh) 2018-12-07
NZ701945A (en) 2016-10-28
KR20150008192A (ko) 2015-01-21
NZ724828A (en) 2018-02-23
WO2013173557A1 (en) 2013-11-21
JP6195611B2 (ja) 2017-09-13
CN104487095A (zh) 2015-04-01
CN109620963A (zh) 2019-04-16
WO2013173543A1 (en) 2013-11-21
CA2873756A1 (en) 2013-11-21
KR20210099187A (ko) 2021-08-11
MX2014013919A (es) 2015-06-05
KR102326360B1 (ko) 2021-11-15
JP2015520163A (ja) 2015-07-16
JP6711935B2 (ja) 2020-06-17
AU2013204754C1 (en) 2018-10-11
CA2873756C (en) 2022-08-16
KR102237306B1 (ko) 2021-04-08
CN109620963B (zh) 2022-10-28
SG10201911328QA (en) 2020-01-30
JP6560712B2 (ja) 2019-08-14
EA028186B1 (ru) 2017-10-31
JP2020111599A (ja) 2020-07-27
BR112014028636A2 (ja) 2017-08-15
EA201790935A1 (ru) 2017-12-29
NZ738844A (en) 2018-12-21
KR20200053636A (ko) 2020-05-18
AU2013204754B2 (en) 2015-11-05
JP2022034075A (ja) 2022-03-02
MX360594B (es) 2018-11-09
EP2849794A1 (en) 2015-03-25
SG10201701780RA (en) 2017-04-27
BR112014028636B1 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
GB201721108D0 (en) Catalyst blends
GB2502030B (en) Catalysts
ZA201307534B (en) Catalysts
EP2825850A4 (en) SEGMENT VALIDATION
GB201116713D0 (en) Catalyst
HK1208197A1 (en) Reduction catalysts
EP2786902A4 (en) DEVICE FOR ACTUATING A VEHICLE
HK1209024A1 (en) Nucleophilic catalysts for oxime linkage
SG10201913078SA (en) Nucleophilic catalysts for oxime linkage
EP2700447A4 (en) SILICONE OXIDE FILLED CATALYST
EP2859438A4 (en) OPERATING SYSTEM
ZA201404910B (en) Catalysts
AU2013204754A1 (en) Nucleophilic Catalysts for Oxime Linkage
ZA201409034B (en) Catalysts
AP3757A (en) Catalysts
HRP20190552T1 (hr) Mehanizam za sklopive krevete na kat
GB2508511B (en) Bimetallic catalyst
GB201220691D0 (en) A catalyst
EP2752241A4 (en) CATALYST
EP2753627A4 (en) CATALYSIS
HK1212895A1 (zh) 用於免疫調節的沙奎那韋-
GB2488127B (en) Operation system for umbrellas
GB201213825D0 (en) Damper-device for bouncing-device
GB201102101D0 (en) Catalysts
AP00334S1 (en) Dustbin